|
1 Indications And Usage Vectibix Is An Epidermal Growth Factor Receptor (Egfr) Antagonist Indicated For The Treatment Of Wild-Type Ras (Defined As Wild-Type In Both Kras And Nras As Determined By An Fda-Approved Test For This Use ) Metastatic Colorectal Cancer (Mcrc): In Combination With Folfox For First-Line Treatment. ( 1.1 , 14.2 ) As Monotherapy Following Disease Progression After Prior Treatment With Fluoropyrimidine, Oxaliplatin, And Irinotecan-Containing Chemotherapy. ( 1.1 , 14.1 ) Limitation Of Use: Vectibix Is Not Indicated For The Treatment Of Patients With Ras -Mutant Mcrc Or For Whom Ras Mutation Status Is Unknown. ( 1.1 , 2.1 , 5.2 , 12.1 ) 1.1 Metastatic Colorectal Cancer Vectibix Is Indicated For The Treatment Of Patients With Wild-Type Ras (Defined As Wild-Type In Both Kras And Nras As Determined By An Fda-Approved Test For This Use) Metastatic Colorectal Cancer (Mcrc) [See Dos Age And Administration ( 2.1 )] : • As First-Line Therapy In Combination With Folfox [ See Clinical Studies ( 14.2 )] . • As Monotherapy Following Disease Progression After Prior Treatment With Fluoropyrimidine-, Oxaliplatin-, And Irinotecan-Containing Chemotherapy [See Clinical Studies ( 14.1 )] . Limitation Of Use: Vectibix Is Not Indicated For The Treatment Of Patients With Ras -Mutant Mcrc Or For Whom Ras Mutation Status Is Unknown [See Dosage And Administration ( 2.1 ) , Warnings And Precautions ( 5.2 ) , And Clinical Pharmacology ( 12.1 ) ].
|